Wedmont Private Capital’s Bio-Techne TECH Stock Holding History

Wedmont Private Capital’s Portfolio TECH Stock Details TECH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,381	Closed	-$201K	–	532
2023 Q2	$201K	Buy	+2,381	New	+$191K	0.02%	477
2023 Q1	–	Sell	-2,707	Closed	-$223K	–	489
2022 Q4	$223K	Buy	+2,707	New	+$215K	0.03%	405
2022 Q2	–	Sell	-2,352	Closed	-$254K	–	382
2022 Q1	$254K	Buy	+2,352	New	+$243K	0.06%	266

Other funds holding TECH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

DDC

DF Dent & Co Baltimore, Maryland $5.27B AUM 7.89% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wedmont Private Capital's TECH Position: Q3 2023 in Review

Wedmont Private Capital sold out of Bio-Techne (TECH) in Q3 2023, closing a stake of 2,381 shares — an estimated $201K sold.

Wedmont Private Capital first reported a position in TECH in Q1 2022 and held it in 3 quarters. The position peaked at $254K in Q1 2022. 530 funds tracked by Wall St. Rank hold TECH as of Q3 2023.

Wedmont Private Capital reported no remaining Bio-Techne position as of Q3 2023 after selling out during the quarter.
Wedmont Private Capital sold 2,381 Bio-Techne shares in Q3 2023, an estimated $201K.
Wedmont Private Capital first reported a position in Bio-Techne in Q1 2022 and held it in 3 quarters.
Wedmont Private Capital's Bio-Techne position peaked at $254K in Q1 2022.
530 funds tracked by Wall St. Rank held Bio-Techne as of Q3 2023.

Based on Wedmont Private Capital's 13F filing for Q3 2023, filed 10 Oct 2023.